HomeBUSINESS
BUSINESS

I/O in Lung Cancer - 5: Roche Looks Beyond Tecentriq, Laying Foundation for Next-Gen Immunotherapies
(Sep.13.2018)

Chugai Executive Vice President Yasushi Ito

By Takashi Ebisawa

 

So far this year, Roche has delivered positive data for its PD-L1 inhibitor Tecentriq (atezolizumab) in first-line lung cancer settings, though rival Merck seems to be solidifying its lead with its I/O behemoth Keytruda (pembrolizumab). Yasushi Ito, executive vice president of Chugai Pharmaceutical, which is majority owned by the Swiss giant, sat with Jiho to share the group’s development strategies ...

(LOG IN FOR FULL STORY)

News Calendar